AbbVie, Inc. (NYSE:ABBV) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 10:00 AM ET Company Participants Robert Michael - President & COO Jeffrey Stewart - EVP & Chief Commercial Officer Roopal Thakkar - SVP & Chief Medical Officer, Global Therapeutics Scott Reents - EVP & CFO Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Welcome everybody. Glad that you can join us. My name is Chris Shibutani, member at the Goldman Sachs Healthcare Research team. We are ...

AbbVie, Inc. (NYSE:ABBV) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 10:00 AM ET Company Participants Robert Michael - President & COO Jeffrey Stewart - EVP & Chief Commercial Officer Roopal Thakkar - SVP & Chief Medical Officer, Global Therapeutics Scott Reents - EVP & CFO Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Welcome everybody. Glad that you can join us. My name is Chris Shibutani, member at the Goldman Sachs Healthcare Research team. We are ...

When it comes to targeting discounted ideas in the equities sector, undervalued blue-chip stocks offer some of the most compelling prospects. First and foremost, blue chips earn the status through decades of business and earnings expansion. In other words, they’re predictable stalwarts that can be depended on in good times and bad.As an investor, understanding this point gives you a clear advantage. Usually, when you hear about a “cheap” security in the financial information sector, it’s tied to an exciting ...

EXTON, PA, June 12, 2024 (GLOBE NEWSWIRE) -- Despite being the second IL-23 inhibitor to enter the market, AbbVie’s Skyrizi (risankizumab) is expected to have a substantial impact on ulcerative colitis (UC) treatment. Spherix Global Insights recently conducted the Q2 2024 wave of its UC RealTime Dynamix™ study, assessing the perspectives of gastroenterologists (n=101) on pipeline agents in development for UC, including Skyrizi. While Eli Lilly’s Omvoh, another IL-23 inhibitor, was approved in late 2023, ov ...

For The Second Year, 20 Women Entrepreneurs Will Each Receive $25,000 In Funding, Plus Access to Mentorship and Community—Helping to Close the Confidence GapIRVINE, Calif., June 11, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV) revealed this year's 20 BOTOX® Cosmetic grant recipients. Each inspiring woman entrepreneur will receive a $25,000 grant, mentorship, and access to community through the BOTOX® Cosmetic grant program in partnership with IFundWomen. The winners were h ...

AbbVie (ABBV) ended the recent trading session at $170.46, demonstrating a +0.61% swing from the preceding day's closing price. This change outpaced the S&P 500's 0.26% gain on the day. At the same time, the Dow added 0.18%, and the tech-heavy Nasdaq gained 0.35%.The drugmaker's stock has climbed by 5.39% in the past month, exceeding the Medical sector's gain of 3.06% and the S&P 500's gain of 3.25%.The investment community will be paying close attention to the earnings performance of AbbVie in its upcoming ...

Company Overview - AbbVie announced positive topline results from the phase II PICCOLO study for Elahere, achieving an objective response rate (ORR) of 51.9% in patients with FRα-positive platinum-sensitive ovarian cancer [1] - The median duration of response (DOR) was reported at 8.25 months, but it was not confirmed if this met the study goal [1] - Elahere has received full FDA approval for treating FRα-positive, platinum-resistant ovarian cancer and is also approved in Europe [2] Drug Development and Pipeline - Elahere is being evaluated in multiple studies as both monotherapy and in combination with other drugs, aiming to expand its use in earlier lines of therapy [2] - AbbVie acquired ImmunoGen for $10.1 billion, adding Elahere and other promising antibody-drug conjugates (ADCs) to its oncology pipeline [2] - Other ADC candidates in AbbVie's pipeline include pivekimab sunirine and IMGN-151, which are in various stages of clinical trials [2] Industry Trends - The ADC market is gaining traction, with significant investments from major pharmaceutical companies like AstraZeneca, Merck, and Pfizer [3][6] - AstraZeneca's Enhertu has shown strong market uptake, generating approximately $339 million in alliance revenues in Q1 2024 [4] - Pfizer's acquisition of Seagen for $43 billion has added three ADCs to its portfolio, enhancing its presence in the ADC space [5] Market Performance - AbbVie's shares have increased by 8.8% over the year, compared to the industry's growth of 18.9% [2] - AbbVie currently holds a Zacks Rank 3 (Hold) [7]

Core Insights - Falling interest rates are leading money managers to shift towards income-oriented equities, particularly high-yield dividend stocks, as they offer yields above the S&P 500 [1] - The Federal Reserve may soon cut rates due to signs of a cooling labor market and core inflation, which is favorable for dividend stock investments [1] AbbVie (NYSE: ABBV) - AbbVie offers a dividend yield of 3.59% and has achieved a 10% annual dividend growth rate over the past five years, surpassing the 6% average among top dividend growers [2] - The stock trades at under 15 times forward earnings, making it attractively priced compared to the S&P 500's nearly 21 times forward earnings multiple [2] - Over the past five years, ABBV shares have appreciated by 117.71% [2] - AbbVie is managing the transition from the loss of market exclusivity for Humira, with strong sales from newer drugs like Skyrizi and Rinvoq, and Vraylar exceeding expectations [4][5] Pfizer (NYSE: PFE) - Pfizer has a dividend yield of 5.76% and is priced at less than 13 times future earnings, positioning it for potential outperformance over the next 10 to 20 years [6] - Despite trading below the S&P 500, Pfizer is a major player in the pharmaceutical industry with a promising pipeline [7] - PFE stock has declined by 29.17% over the past five years, primarily due to reduced revenue from COVID-19 product sales post-pandemic [8] - Pfizer's focus on oncology, which has strong pricing power, is often overlooked, but it remains a significant aspect of its long-term strategy [8] - Both AbbVie and Pfizer are suitable options for investors seeking high yields on long-term investments [8]

AbbVie (ABBV) dosed the first patient with ABBV-383, an investigational BCMA-CD3-targeted bispecific antibody, in the phase III CERVINO study to treat relapsed/refractory (r/r) multiple myeloma (MM).The CERVINO study will enroll nearly 380 patients with r/r MM who have received at least two lines of prior therapy. Patients will be randomized into two equal groups — either to receive a 60mg dose of intravenously-administered ABBV-383 once every four weeks or the investigator's choice of standard available th ...

Group 1 - AbbVie announced positive topline results from the Phase 2 PICCOLO trial for mirvetuximab soravtansine (ELAHERE®) in patients with platinum-sensitive ovarian cancer, achieving an objective response rate (ORR) of 51.9% [1] - The median duration of response (DOR) was reported at 8.25 months, indicating promising efficacy [1] - The safety profile of mirvetuximab soravtansine was consistent with previous studies, with no new safety concerns identified [1] Group 2 - The PICCOLO trial is a single-arm Phase 2 study focusing on patients with high folate receptor-alpha (FRα) positive platinum-sensitive ovarian cancer who have undergone at least two prior lines of platinum therapy [3] - The trial was designed to statistically rule out an ORR of 28% or lower, which is the response rate observed with non-platinum, single-agent chemotherapy in similar patient populations [3] - There is a significant unmet need for effective treatments in this patient group, as subsequent lines of therapy often show decreased efficacy and tolerability [2] Group 3 - Mirvetuximab soravtansine is also being evaluated in the Phase 3 GLORIOSA trial, which studies its combination with bevacizumab versus bevacizumab alone in maintenance therapy after second-line platinum-doublet therapy [4] - Ovarian cancer remains the leading cause of death from gynecological cancers in the U.S., with approximately 20,000 new diagnoses each year [5] - Patients who relapse after platinum-based chemotherapy are classified as either platinum-sensitive or platinum-resistant, impacting treatment options and outcomes [5][6] Group 4 - Mirvetuximab soravtansine is a first-in-class antibody-drug conjugate (ADC) designed to target and kill cancer cells expressing folate receptor alpha [7] - The drug has received regulatory approval in the U.S. for treating FRα positive, platinum-resistant ovarian cancer and is under review in Europe and other countries [8]